Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China

Authors: Yun Zhuo Chu, Su Fei Tian, Bai Yi Chen, Hua Nian, Hong Shang, Guo Quan Sun

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

To examine common antimicrobial regimens used in eradicating certain nosocomial Gram-negative pathogens and determine which ones are likely to be the most suitable as empirical choices in Shenyang, China.

Methods

A 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response (CFR) for meropenem, imipenem, cefepime, piperacillin/tazobactam and levofloxacin against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Pseudomonas aeruginosa collected in 2006 and 2007 from Shenyang.

Results

Meropenem and imipenem had the highest CFRs against the Enterobacteriaceae (97%-100%), followed by cefepime. No antibiotic simulated regimen achieved optimal CFR against P. aeruginosa and A. baumannii. Piperacillin/tazobactam dosed at 4.5 g q8h achieved the lowest CFR against all bacteria.

Conclusions

This study suggests that the carbapenems provide the greatest likelihood of clinical success for the Enterobacteriaceae, and combination therapy might be needed when choosing empirical therapy, especially when A. baumannii or P. aeruginosa are suspected.
Literature
1.
go back to reference Bradley JS, Dudley MN, Drusano GL: Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003, 22 (11): 982-992. 10.1097/01.inf.0000094940.81959.14.CrossRefPubMed Bradley JS, Dudley MN, Drusano GL: Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003, 22 (11): 982-992. 10.1097/01.inf.0000094940.81959.14.CrossRefPubMed
2.
go back to reference Kuti JL, Nightingale CH, Nicolau DP: Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrob Agents Chemother. 2004, 48 (2): 2464-2470. 10.1128/AAC.48.7.2464-2470.2004.CrossRefPubMedPubMedCentral Kuti JL, Nightingale CH, Nicolau DP: Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrob Agents Chemother. 2004, 48 (2): 2464-2470. 10.1128/AAC.48.7.2464-2470.2004.CrossRefPubMedPubMedCentral
3.
go back to reference Frei CR, Wiederhold NP, Burgess DS: Antimicrobial breakpionts for Gram-negative aerobic bacteria based on pharmacokinetic-pharmadynamic models with Monte Carlo simulation. J Antimicrob Chemother. 2008, 61 (3): 621-628. 10.1093/jac/dkm536.CrossRefPubMedPubMedCentral Frei CR, Wiederhold NP, Burgess DS: Antimicrobial breakpionts for Gram-negative aerobic bacteria based on pharmacokinetic-pharmadynamic models with Monte Carlo simulation. J Antimicrob Chemother. 2008, 61 (3): 621-628. 10.1093/jac/dkm536.CrossRefPubMedPubMedCentral
4.
go back to reference Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G: Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992, 36 (12): 2794-2798.CrossRefPubMedPubMedCentral Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G: Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992, 36 (12): 2794-2798.CrossRefPubMedPubMedCentral
5.
go back to reference Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001, 45 (1): 13-22. 10.1128/AAC.45.1.13-22.2001.CrossRefPubMedPubMedCentral Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001, 45 (1): 13-22. 10.1128/AAC.45.1.13-22.2001.CrossRefPubMedPubMedCentral
6.
go back to reference Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005, 55 (5): 601-607. 10.1093/jac/dki079.CrossRefPubMed Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005, 55 (5): 601-607. 10.1093/jac/dki079.CrossRefPubMed
7.
go back to reference Mattoes HM, Kuti JL, Drusano GL, Nicolau DP: Optimizing Antimicrobial Pharmacodynamics: Dosage Strategies for Meropenem. Clin Ther. 2004, 26 (8): 1187-1198. 10.1016/S0149-2918(04)80001-8.CrossRefPubMed Mattoes HM, Kuti JL, Drusano GL, Nicolau DP: Optimizing Antimicrobial Pharmacodynamics: Dosage Strategies for Meropenem. Clin Ther. 2004, 26 (8): 1187-1198. 10.1016/S0149-2918(04)80001-8.CrossRefPubMed
8.
go back to reference Chamot E, Boffi El Amari E, Rohner P, Van Delden C: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003, 47 (9): 2756-2764. 10.1128/AAC.47.9.2756-2764.2003.CrossRefPubMedPubMedCentral Chamot E, Boffi El Amari E, Rohner P, Van Delden C: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2003, 47 (9): 2756-2764. 10.1128/AAC.47.9.2756-2764.2003.CrossRefPubMedPubMedCentral
9.
go back to reference Wang H, Zhang B, Ni Y, Kuli JL, Chen B, Chen M, Nicolau DP: Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007, 30 (5): 452-457. 10.1016/j.ijantimicag.2007.06.005.CrossRefPubMed Wang H, Zhang B, Ni Y, Kuli JL, Chen B, Chen M, Nicolau DP: Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007, 30 (5): 452-457. 10.1016/j.ijantimicag.2007.06.005.CrossRefPubMed
10.
go back to reference Kuti JL, Nicolau DP: Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis. 2005, 53 (4): 281-287. 10.1016/j.diagmicrobio.2005.10.004.CrossRefPubMed Kuti JL, Nicolau DP: Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis. 2005, 53 (4): 281-287. 10.1016/j.diagmicrobio.2005.10.004.CrossRefPubMed
11.
go back to reference Kuti JL, Horowitz S, Nightingale CH, Nicolau DP: Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy. 2005, 25 (7): 935-941. 10.1592/phco.2005.25.7.935.CrossRefPubMed Kuti JL, Horowitz S, Nightingale CH, Nicolau DP: Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy. 2005, 25 (7): 935-941. 10.1592/phco.2005.25.7.935.CrossRefPubMed
Metadata
Title
Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang, China
Authors
Yun Zhuo Chu
Su Fei Tian
Bai Yi Chen
Hua Nian
Hong Shang
Guo Quan Sun
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-171

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.